Generic companies ink hepatitis C deal with BMS

Pharmaceutical companies including Cipla and Natco Pharma have signed a sub-licensing deal enabling them to produce a generic version of Bristol Myers Squibb’s (BMS) hepatitis C drug Daclatasvir (daklinza).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Africa

Explainer: ARIPO’s role in Plant Variety Protection

15 July 2025 Africa’s agricultural future is imperative to life and prosperity in the region—and the Arusha Protocol gives breeders the protection they need, explains the African Regional Intellectual Property Organization.

Africa

Commercialising genomic tech in Nigeria

29 April 2025 Genomic innovations involve vast amounts of research, making patents, copyrights, and trade secrets vital, explains Olusola Tunmise-Ajani of Inventa International.

Africa

J&J pledges not to enforce TB patents in certain countries

3 October 2023 Non-profit hails move but urges other big pharma companies to follow suit | To avoid litigation, manufacturers must ensure generic versions are of good quality, medically acceptable, and are used only in the selected low-and middle-income countries.

More features

Court narrows Mylan’s Copaxone suit but key claims survive

IP finance gap risks startup exodus, EUIPO warns

Oracle retaliates with lawsuit to laid-off staff member’s ‘demands’

LSPN Awards USA: Meet the judges

UK patent office adopts EPO standards for AI inventions

Faegre Drinker boosts FDA regulatory practice with two senior hires

Gilead to pay up to $5bn for antibody-drug conjugates push

Closing the women's health gap offers ‘benefits for all’

Generic companies ink hepatitis C deal with BMS

More on this story

Editor's picks

Editor's picks

More features